Accepted Manuscript

A new promising candidate to overcome drug resistant herpes simplex virus infections

Elisabeth Zinser, Adalbert Krawczyk, Petra Mühl-Zürbes, Ulrich Aufderhorst, Lena Stich, Mirko Zaja, Stefan Strobl, Alexander Steinkasserer, Christiane Silke Heilingloh

PII: S0166-3542(17)30538-7

DOI: 10.1016/j.antiviral.2017.11.012

Reference: AVR 4193

To appear in: *Antiviral Research*

Received Date: 27 July 2017

Revised Date: 13 November 2017

Accepted Date: 14 November 2017

Please cite this article as: Zinser, E., Krawczyk, A., Mühl-Zürbes, P., Aufderhorst, U., Stich, L., Zaja, M., Strobl, S., Steinkasserer, A., Heilingloh, C.S., A new promising candidate to overcome drug resistant herpes simplex virus infections, *Antiviral Research* (2017), doi: 10.1016/j.antiviral.2017.11.012.

A new promising candidate to overcome drug resistant herpes simplex virus infections

Elisabeth Zinser[a#], Adalbert Krawczyk[b#], Petra Mühl-Zürbes[a], Ulrich Aufderhorst[b], Lena Stich[a], Mirko Zaja[c1], Stefan Strobl[c1], Alexander Steinkasserer[a], Christiane Silke Heilingloh[a*]

[a] Department of Immune Modulation, University Hospital Erlangen, Erlangen, Germany

[b] Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

[c] 4SC Discovery GmbH, Martinsried, Germany

[1] Current affiliation: BioNTech Small Molecules GmbH, Planegg-Martinsried, Germany.

[#] contributed equally to this work

[*] Corresponding author: Christiane Silke Heilingloh: christiane.heilingloh@uk-erlangen.de

Department of Immune Modulation, Hartmannstr. 14, 91052 Erlangen, Germany

Keywords: Herpes simplex virus; antiviral therapy; acyclovir resistance